Understand the source comparison
Top Selling Peptides January 2026: Research Category Comparison
The following table compares the leading research peptides across metabolic, cognitive, and recovery categories based on order volume, mechanism specificity, and published trial data as of January 2026. Tirzepatide Dual GIP/GLP-1 receptor agonist Metabolic / W
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares the leading research peptides across metabolic, cognitive, and recovery categories based on order volume, mechanism specificity, and published trial data as of January 2026.
- Tirzepatide
- Dual GIP/GLP-1 receptor agonist
- Metabolic / Weight Loss
- ~5 days
- SURMOUNT-1: 20.9% mean weight reduction at 72 weeks (15mg dose)
- Gold standard for incretin-driven metabolic research. Most-cited GLP-1 compound in 2025–2026 publications
- Semaglutide
- GLP-1 receptor agonist
- ~7 days
- STEP-1: 14.9% mean weight reduction at 68 weeks (2.4mg dose)
- Longest safety profile in category. Preferred for chronic dosing studies
- BPC-157
- Angiogenesis / VEGF modulation
- Tissue Repair
- ~4 hours
- University of Zagreb rodent models: accelerated tendon healing, reduced inflammation
- Leading bioregulator for soft tissue repair research. Most-ordered recovery peptide
- Semax Amidate
- BDNF modulation / monoamine regulation
- Cognitive / Nootropic
- ~30 minutes (blood), tissue effects sustained 8–12 hours
- 50+ Russian studies: neuroprotection, cognitive resilience under stress
- Reference nootropic for neuroplasticity studies. 140% YoY growth
- TB-500
- Actin sequestration / cell migration
- ~10 days
- Wound healing models: keratinocyte migration, angiogenesis, NF-κB inhibition
- Second-ranking recovery peptide. Preferred for long-duration injury models
- Dihexa
- HGF modulation / synaptogenesis
- ~2 hours
- WSU research: 7–8× BDNF potency in hippocampal synapse formation
- Fastest-onset nootropic peptide. Synaptogenesis detectable within 72 hours
- Tirzepatide's dominance reflects the metabolic research community's preference for dual-agonist mechanisms that allow isolation of incretin-specific effects without sympathomimetic confounds. Semax's rapid growth in cognitive research stems from its combination of published mechanism data and emerging Western replication studies validating earlier Russian findings. BPC-157 remains the most-ordered recovery peptide despite its lack of human trials, a testament to the strength of its preclinical tissue repair data and the absence of competing compounds with comparable soft tissue healing documentation.